Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Apr 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2021 Apr 20;20(4):953–955.e2. doi: 10.1016/j.cgh.2021.04.018

Table 1:

Comparison of the patient-level true positive rate at the 10% screening-level false positive rate in the overall cohort

	Any-stage HCC		Early-stage HCC
	Any time prior to diagnosis	0–6 months prior to diagnosis	Any time prior to diagnosis	0–6 months prior to diagnosis
GALAD	51.7 (95%CI: 29.–68.8)	71.4 (95% CI: 28.6–92.3)	57.9 (95% CI: 29.4–80.0)	70.0 (95%CI: 18.2–100.0)
Doylestown Plus	65.5 (95%CI: 47.6–92.6)	78.6 (95%CI: 50.0–100.0)	63.2 (95%CI: 37.5–93.8)	80.0 (95%CI: 42.9–100.0)
AFP	37.9 (95%CI: 23.3–68.2)	57.1 (95%CI: 33.3–90.0)	47.4 (95%CI: 25.0–75.0)	70.0 (95%CI: 37.5–100.0)
AFP-L3%	55.2 (95%CI: 28.1–73.1)	61.5 (95%CI: 26.7–84.6)	52.6 (95%CI: 17.6–75.0)	55.6 (95%CI: 11.7–83.3)
DCP	20.7 (95%CI: 0.0–41.4)	7.1 (95%CI: 0.0–26.7)	26.3 (95%CI: 0.0–52.6)	10.0 (95%CI: 0.0–33.3)